VitiligoVitiligo is a chronic skin disorder characterized by the progressive loss of melanocytes, leading to depigmented patches on the skin, which can significantly affect patients’ quality of life and self-esteem. Traditional treatments for vitiligo, such as topical corticosteroids and phototherapy, often yield limited results and can be time-consuming. Janus kinase (JAK) inhibitors targeting specific pathways involved in the autoimmune processes that contribute to melanocyte destruction. These small molecules act by inhibiting JAK enzymes, which play a critic role in the signaling pathways of different cytokines that mediate inflammation and immune responses. Recent clinical trials have demonstrated the efficacy of JAK inhibitors in promoting repigmentation in vitiligo patients, showcasing their potential superiority over conventional therapies. However, the clinical application of JAK inhibitors is not without challenges, including a spectrum of side effects and concerns regarding long-term safety. Understanding the mechanisms of action, efficacy, and safety profiles of JAK inhibitors in vitiligo treatment is essential for optimizing patient outcomes. Furthermore, the selection of suitable candidates for JAK inhibitor therapy and the integration of personalized medicine approaches could enhance therapeutic responses. As research in this field progresses, exploring combination therapies and identifying biomarkers predictive of treatment response will be critical in refining treatment strategies and improving the overall management of vitiligo. This paper aims to provide a comprehensive overview of the role of JAK inhibitors in vitiligo, addressing their mechanism of action, clinical efficacy, safety considerations, patient selection criteria, and future research directions, thereby contributing to a deeper understanding of this innovative treatment paradigm in dermatology.